Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 12;75(14):2897–2906. doi: 10.1158/0008-5472.CAN-14-2860

Figure 4.

Figure 4

Pre-treatment with decitabine alters the activity of a subset of small-molecule probes. A, cell viability was measured after co-treatment with vorinostat and decitabine for three days or after pre-treatment with decitabine or DMSO for nine days followed by co-treatment with vorinostat and decitabine for three days (two biological replicates, mean ± SD). B, Thirty-four cancer cell lines were pre-treated with decitabine (0.5 µM) or DMSO for nine days. Viable cells were harvested and co-treated with decitabine (0.5 µM) or DMSO and the combination ‘informer set’. Cell viability was measured after three days and normalized to the cell state tested. The area under the curve was determined for treatment with decitabine (AUCdecitabine, y-axis) or DMSO (AUCDMSO, x-axis). Data are the mean of two biological replicates. C, the difference between AUCdecitabine and AUCDMSO was plotted for each cell line (x-axis) and each ‘informer set’ compound (y-axis).